Medicine

AD04 Advancing to Phase III Amid Promising Results in Alcohol Use Disorder

January 22, 2025 - By 

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.

Related Posts

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

February 19, 2025

Navigating Distrust: Pharma in the Age of Social Media

February 19, 2025

Pharmaceutical Executive: February 2025 Issue (PDF)

February 18, 2025

Leave a Reply

Your email address will not be published. Required fields are marked *